

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Song 1



| Section 1.                                   | Identifying Inform                           | nation  |  |
|--|--|---|--|
| 1. Given Name (Fii<br>Yang                   | rst Name)                                    | 2. Surname (Last Name)<br>Song                              | 3. Date<br>18-March-2020   |
| 4. Are you the cor                           | responding author?                           | Yes ✓ No  | Corresponding Author's Name<br>Naixin Liang, Shanqing Li   |
| 5. Manuscript Title<br>Potential treatme     |  | e osimertinib resistant mu                                  | tation EGFR L718Q  |
| 6. Manuscript Ider<br>JTD-20-1004(AZ-        | ntifying Number (if you kr<br>-2019-CR-02-F) | now it)   |  |
|  |  |   |  |
| Section 2.                                   | The Work Under Co                            | onsideration for Public                                     | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                     | g but not limited to grants, da                             | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial                           | activities outside the s                                    | ubmitted work.   |
| of compensation clicking the "Add            | ) with entities as descri                    | ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication. |
| Section 4.                                   | Intellectual Proper                          | rty Patents & Copyric                                       | ghts   |
| Do you have any                              | patents, whether plan                        | ned, pending or issued, br                                  | oadly relevant to the work? Yes V No   |

Song 2



| Section 5.                 |   |
|----------------------------|---|
| Section 5.                 | Relationships not covered above   |
|                            | elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?  |
| Yes, the follow            | ving relationships/conditions/circumstances are present (explain below):  |
| ✓ No other relat           | tionships/conditions/circumstances that present a potential conflict of interest  |
|                            | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>nals may ask authors to disclose further information about reported relationships. |
| Section 6.                 | Disclosure Statement  |
| Based on the abo<br>below. | ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Song has not           | hing to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Song 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Jia 1



| Section 1.  | Identifying Inform                        | ation   |  |  |
|---|---|---|--|--|
| 1. Given Name (First<br>Ziqi                      | t Name)                                   | 2. Surname (Last Name)<br>Jia                               | 3. Date<br>18-March-2020   |  |
| 4. Are you the corre                              | esponding author?                         | ☐ Yes ✓ No  | Corresponding Author's Name<br>Naixin Liang, Shanqing Li   |  |
| 5. Manuscript Title<br>Potential treatmer         | nt strategy for the rare                  | e osimertinib resistant mu                                  | tation EGFR L718Q  |  |
| 6. Manuscript Ident<br>JTD-20-1004(AZ-2           | ifying Number (if you kn<br>1019-CR-02-F) | ow it)  |  |  |
|   |   |   | _  |  |
| Section 2.  | The Work Under Co                         | onsideration for Public                                     | cation   |  |
| any aspect of the sul<br>statistical analysis, et | bmitted work (including                   | but not limited to grants, da                               | a third party (government, commercial, private foundation, etc.) for<br>ita monitoring board, study design, manuscript preparation,  |  |
| Section 3.  | Relevant financial                        | activities outside the s                                    | submitted work.  |  |
| of compensation)<br>clicking the "Add -           | with entities as descri                   | bed in the instructions. Use<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |  |
| Section 4.  | Intellectual Proper                       | ty Patents & Copyri   | ghts   |  |
| Do you have any p                                 | patents, whether planr                    | ned, pending or issued, br                                  | oadly relevant to the work? Yes V No   |  |

Jia 2



| Section 5. Polationships not severed above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Jia has nothing to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Jia 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



| Section 1.   | Identifying Inform                                    | nation  |   |
|--|---|---|---|
| 1. Given Name (Fi<br>Yadong                          | rst Name)   | 2. Surname (Last Name)<br>Wang                              | 3. Date<br>18-March-2020  |
| 4. Are you the cor                                   | responding author?                                    | Yes ✓ No  | Corresponding Author's Name<br>Naixin Liang, Shanqing Li  |
| 5. Manuscript Title<br>Potential treatm              |   | e osimertinib resistant mu                                  | tation EGFR L718Q   |
| 6. Manuscript Ide<br>JTD-20-1004(AZ                  | ntifying Number (if you kr<br>-2019-CR-02-F)          | now it)   |   |
|  |   |   |   |
| Section 2.   | The Work Under C                                      | onsideration for Public                                     | cation  |
| any aspect of the s<br>statistical analysis,         | submitted work (including                             | but not limited to grants, da                               | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,  |
| Section 3.   |   |   |   |
| Place a check in a of compensation clicking the "Add | the appropriate boxes i<br>n) with entities as descri | ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by the present during the 36 months prior to publication. |
| Section 4.   | Intellectual Prope                                    | rty Patents & Copyrig                                       | ghts  |
| Do you have any                                      | patents, whether plan                                 | ned, pending or issued, br                                  | oadly relevant to the work? Yes V No  |



| Section 5.                 |  |
|----------------------------|--|
|                            | Relationships not covered above  |
|                            | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follo             | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela            | tionships/conditions/circumstances that present a potential conflict of interest   |
|                            | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships. |
| Section 6.                 | Disclosure Statement   |
| Based on the abo<br>below. | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Wang has no            | othing to disclose.  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



| Section 1.   | Identifying Inform                                    | nation  |  |
|--|---|---|--|
| 1. Given Name (Fi<br>Yanyu                           | rst Name)   | 2. Surname (Last Name)<br>Wang                              | 3. Date<br>18-March-2020   |
| 4. Are you the cor                                   | responding author?                                    | Yes ✓ No  | Corresponding Author's Name<br>Naixin Liang, Shanqing Li   |
| 5. Manuscript Title<br>Potential treatm              |   | e osimertinib resistant mu                                  | tation EGFR L718Q  |
| 6. Manuscript Ide<br>JTD-20-1004(AZ                  | ntifying Number (if you kr<br>-2019-CR-02-F)          | now it)   |  |
|  |   |   |  |
| Section 2.   | The Work Under Co                                     | onsideration for Public                                     | cation   |
| any aspect of the s<br>statistical analysis,         | submitted work (including                             | but not limited to grants, da                               | a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,   |
| Section 3.   |   |   |  |
| Place a check in a of compensation clicking the "Add | the appropriate boxes i<br>n) with entities as descri | ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Section 4.   | Intellectual Prope                                    | rty Patents & Copyrig                                       | ghts   |
| Do you have any                                      | patents, whether plan                                 | ned, pending or issued, br                                  | oadly relevant to the work? Yes V No   |



| Section 5.                 |  |
|----------------------------|--|
|                            | Relationships not covered above  |
|                            | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follo             | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela            | tionships/conditions/circumstances that present a potential conflict of interest   |
|                            | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships. |
| Section 6.                 | Disclosure Statement   |
| Based on the abo<br>below. | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Wang has no            | othing to disclose.  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Liu 1



| Section 1. Identifying Inform   | ation  |  |  |
|---|--|--|--|
| 1. Given Name (First Name)<br>Peng  | 2. Surname (Last Name)<br>Liu                              | 3. Date<br>18-March-2020   |  |
| 4. Are you the corresponding author?  | ☐ Yes ✓ No   | Corresponding Author's Name<br>Naixin Liang, Shanqing Li   |  |
| 5. Manuscript Title<br>Potential treatment strategy for the rare            | e osimertinib resistant mu                                 | tation EGFR L718Q  |  |
| 6. Manuscript Identifying Number (if you kr<br>JTD-20-1004(AZ-2019-CR-02-F) | now it)  |  |  |
|   |  |  |  |
| Section 2. The Work Under Co  | onsideration for Public                                    | cation   |  |
|   | but not limited to grants, da                              | a third party (government, commercial, private foundation, etc.) for<br>ita monitoring board, study design, manuscript preparation,  |  |
| Section 3. Relevant financial   | activities outside the s                                   | submitted work.  |  |
| of compensation) with entities as descri                                    | bed in the instructions. Use<br>port relationships that we | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |  |
| Section 4. Intellectual Proper  |  |  |  |
| Intellectual Proper   | ty Patents & Copyri  | hts  |  |
| Do you have any patents, whether plan                                       | ned, pending or issued, br                                 | roadly relevant to the work? Yes V No  |  |

Liu 2



| Section 5.                 |   |
|----------------------------|---|
|                            | Relationships not covered above   |
|                            | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?   |
| Yes, the follo             | wing relationships/conditions/circumstances are present (explain below):  |
| ✓ No other rela            | tionships/conditions/circumstances that present a potential conflict of interest  |
|                            | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.                 | Disclosure Statement  |
| Based on the abo<br>below. | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. Liu has nothi          | ng to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Liu 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Zhang 1



| Section 1. Identifying Inform  | ation   |   |   |  |
|--|---|---|---|--|
| identifying inform   |   |   |   |  |
| Given Name (First Name)     Shuyang  | 2. Surname (Last Name)<br>Zhang                                       |   | 3. Date<br>18-March-2020  |  |
| 4. Are you the corresponding author?   | Yes ✓ No  | Corresponding Author's Name Naixin Liang, Shanqing Li |   |  |
| 5. Manuscript Title Potential treatment strategy for the rare  | e osimertinib resistant mu  | tation EGFR L718Q                                     |   |  |
| 6. Manuscript Identifying Number (if you kn<br>JTD-20-1004(AZ-2019-CR-02-F)  | ow it)  |   |   |  |
|  |   |   |   |  |
| Section 2. The Work Under Co   | onsideration for Public   | cation  |   |  |
| any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of intere  | but not limited to grants, datest? Yes No ormation below. If you have | ta monitoring board, st                               | ent, commercial, private foundation, etc.) for udy design, manuscript preparation, ity press the "ADD" button to add a row. |  |
| Name of Institution/Company  | Grant   | n-Financial other?                                    | Comments  |  |
| National Key Research and Development<br>Program of China Grant  | <b>✓</b>  |   | No. 2016YFC0901500  |  |
|  |   |   |   |  |
| Section 3. Relevant financial  | activities outside the s  | submitted work.                                       |   |  |
| Place a check in the appropriate boxes i<br>of compensation) with entities as descri<br>clicking the "Add +" box. You should rep<br>Are there any relevant conflicts of intere | bed in the instructions. Us<br>port relationships that wer            | se one line for each e                                | ntity; add as many lines as you need by   |  |
| Section 4. Intellectual Proper   | ty Patents & Copyric  | ghts  |   |  |
| Do you have any patents, whether plant   | ned, pending or issued, br  | oadly relevant to the                                 | work? ☐ Yes ✓ No  |  |

Zhang 2



| Section 5. Polationships not severed above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Zhang reports grants from National Key Research and Development Program of China Grant, during the conduct of the study; .   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Zhang 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Bing 1



| Section 1.                                   | Identifying Inform                                   | nation   |  |
|--|--|--|--|
| 1. Given Name (Fi<br>Zhongxing               | rst Name)  | 2. Surname (Last Name)<br>Bing   | 3. Date<br>18-March-2020   |
| 4. Are you the corresponding author?         |  | Yes ✓ No   | Corresponding Author's Name<br>Naixin Liang, Shanqing Li   |
| 5. Manuscript Title<br>Potential treatme     |  | e osimertinib resistant mu   | tation EGFR L718Q  |
| 6. Manuscript Ider<br>JTD-20-1004(AZ-        | ntifying Number (if you kr<br>-2019-CR-02-F)         | now it)  |  |
|  |  |  |  |
| Section 2.                                   | The Work Under Co                                    | onsideration for Public  | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                             | g but not limited to grants, da  | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial                                   | activities outside the s   | submitted work.  |
| of compensation clicking the "Add            | the appropriate boxes i<br>) with entities as descri | in the table to indicate wh<br>ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Section 4.                                   | Intellectual Proper                                  | rty Patents & Copyric  | ghts   |
| Do you have any                              | patents, whether plan                                | ned, pending or issued, br   | oadly relevant to the work? Yes V No   |

Bing 2



| Section 5.   |   |  |
|--|---|--|
|  | Relationships not covered above   |  |
|  | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |  |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):  |  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |   |  |
| Section 6.   | Disclosure Statement  |  |
| Based on the abo<br>below.   | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |
| Dr. Bing has not   | hing to disclose.   |  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Bing 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

paten<sup>.</sup>



| Section 1.                                   | Identifying Inform                          | nation   |  |
|--|---|--|--|
| 1. Given Name (Fi<br>Lei                     | rst Name)                                   | 2. Surname (Last Name)<br>Cao                              | 3. Date<br>18-March-2020   |
| 4. Are you the corresponding author?         |   | Yes ✓ No   | Corresponding Author's Name<br>Naixin Liang, Shanqing Li   |
| 5. Manuscript Title<br>Potential treatme     |   | e osimertinib resistant mu                                 | tation EGFR L718Q  |
| 6. Manuscript Ider<br>JTD-20-1004(AZ-        | ntifying Number (if you kr<br>2019-CR-02-F) | now it)  |  |
|  |   |  |  |
| Section 2.                                   | The Work Under Co                           | onsideration for Public                                    | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                    | but not limited to grants, da                              | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial                          | activities outside the s                                   | submitted work.  |
| of compensation clicking the "Add            | ) with entities as descri                   | bed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount<br>se one line for each entity; add as many lines as you need by<br>se <b>present during the 36 months prior to publication</b> . |
| Section 4.                                   | Intellectual Proper                         | ty Patents & Copyric                                       | yhts   |
| Do you have any                              | patents, whether plan                       | ned, pending or issued, br                                 | oadly relevant to the work? ☐ Yes ✓ No   |



| Section 5.  |   |  |
|---|---|--|
|   | Relationships not covered above   |  |
|   | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |  |
| Yes, the follow   | wing relationships/conditions/circumstances are present (explain below):  |  |
| ✓ No other rela   | tionships/conditions/circumstances that present a potential conflict of interest  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |   |  |
| Section 6.  | Disclosure Statement  |  |
| Based on the abo<br>below.  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |
| Dr. Cao has noth  | ning to disclose.   |  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

paten<sup>.</sup>



| Section 1.                                   | Identifying Inform                              | nation  |  |
|--|---|---|--|
| 1. Given Name (Fi<br>Zhili                   | rst Name)                                       | 2. Surname (Last Name)<br>Cao   | 3. Date<br>18-March-2020   |
| 4. Are you the corresponding author?         |   | ☐ Yes ✓ No  | Corresponding Author's Name<br>Naixin Liang, Shanqing Li   |
| 5. Manuscript Title<br>Potential treatm      |   | e osimertinib resistant mu  | tation EGFR L718Q  |
| 6. Manuscript Ide<br>JTD-20-1004(AZ          | ntifying Number (if you kr<br>-2019-CR-02-F)    | now it)   |  |
|  |   |   |  |
| Section 2.                                   | The Work Under C                                | onsideration for Public   | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                        | g but not limited to grants, da   | a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial                              | activities outside the s  | submitted work.  |
| of compensation clicking the "Add            | the appropriate boxes in with entities as descr | in the table to indicate who<br>ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Section 4.                                   | Intellectual Prope                              | rty Patents & Copyric   | ghts   |
| Do you have any                              |   |   | oadly relevant to the work? Yes V No   |



| Section 5.  |   |  |
|---|---|--|
|   | Relationships not covered above   |  |
|   | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work? |  |
| Yes, the follow   | wing relationships/conditions/circumstances are present (explain below):  |  |
| ✓ No other rela   | tionships/conditions/circumstances that present a potential conflict of interest  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |   |  |
| Section 6.  | Disclosure Statement  |  |
| Based on the abo<br>below.  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |
| Dr. Cao has noth  | ning to disclose.   |  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Rossi 1



| Section 1.                                   | Identifying Inform                                    | nation   |  |
|--|---|--|--|
| 1. Given Name (Fi<br>Elisabetta              | rst Name)   | 2. Surname (Last Name)<br>Rossi  | 3. Date<br>18-March-2020   |
| 4. Are you the cor                           | responding author?                                    | Yes ✓ No   | Corresponding Author's Name<br>Naixin Liang  |
| 5. Manuscript Title<br>Potential treatm      |   | e osimertinib resistant mu   | tation EGFR L718Q  |
| 6. Manuscript Idei<br>JTD-20-1004(AZ         | ntifying Number (if you kr<br>-2019-CR-02-F)          | now it)  |  |
|  |   |  |  |
| Section 2.                                   | The Work Under Co                                     | onsideration for Public  | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                              | but not limited to grants, da  | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial                                    | activities outside the s   | submitted work.  |
| of compensation clicking the "Add            | the appropriate boxes i<br>n) with entities as descri | in the table to indicate wh<br>ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Section 4.                                   | Intellectual Proper                                   | rty Patents & Copyric  | ghts   |
| Do you have any                              |   |  | oadly relevant to the work? Yes V No   |

Rossi 2



| Section 5. Polationships not severed above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Rossi has nothing to disclose.   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Rossi 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

**koyaities:** Funds are coming in to you or your institution due to you! patent

Zamarchi 1



| Section 1.  | Identifying Inform                                   | nation  |  |
|---|--|---|--|
| 1. Given Name (Fii<br>Rita                                  | rst Name)  | 2. Surname (Last Name)<br>Zamarchi                          | 3. Date<br>18-March-2020   |
| 4. Are you the corresponding author?                        |  | ☐ Yes ✓ No  | Corresponding Author's Name<br>Naixin Liang  |
| 5. Manuscript Title<br>Potential treatme                    |  | e osimertinib resistant mu                                  | tation EGFR L718Q  |
| 6. Manuscript Ider<br>JTD-20-1004(AZ-                       | ntifying Number (if you kr<br>-2019-CR-02-F)         | now it)   |  |
|   |  |   |  |
| Section 2.  | The Work Under Co                                    | onsideration for Public                                     | cation   |
| any aspect of the s<br>statistical analysis,                | ubmitted work (including                             | g but not limited to grants, da                             | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.  | Dalaman Caracial                                     |   | ordered to the sale of the sal |
| Place a check in to<br>of compensation<br>clicking the "Add | the appropriate boxes i<br>) with entities as descri | ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by the present during the 36 months prior to publication.  |
| Section 4.  | Intellectual Proper                                  | rty Patents & Copyric                                       | ghts   |
| Do you have any   | patents, whether plan                                | ned, pending or issued, br                                  | oadly relevant to the work? Yes V No   |

Zamarchi 2



| Section 5. Polationships not sovered above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Zamarchi has nothing to disclose.  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Zamarchi 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

DENIS 1



| Section 1.                                   | Identifying Inform         | nation  |  |
|--|----------------------------|---|--|
| 1. Given Name (Fir<br>Marc                   | rst Name)                  | 2. Surname (Last Name)<br>DENIS                             | 3. Date<br>19-March-2020   |
| 4. Are you the corresponding author?         |                            | Yes ✓ No  | Corresponding Author's Name<br>Naixin Liang  |
| 5. Manuscript Title<br>Potential treatme     |                            | e osimertinib resistant mu                                  | tation EGFR L718Q  |
| 6. Manuscript Ider<br>JTD-20-1004            | ntifying Number (if you kr | now it)   |  |
|  |                            |   |  |
| Section 2.                                   | The Work Under Co          | onsideration for Public                                     | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including   | g but not limited to grants, da                             | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial         | activities outside the s                                    | ubmitted work.   |
| of compensation clicking the "Add            | ) with entities as descri  | ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication. |
| Section 4.                                   | Intellectual Proper        | rty Patents & Copyric                                       | ghts   |
| Do you have any                              | patents, whether plan      | ned, pending or issued, br                                  | oadly relevant to the work? Yes V No   |

DENIS 2



| Section 5.                 |  |
|----------------------------|--|
| Section 5.                 | Relationships not covered above  |
|                            | elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?   |
| Yes, the follow            | ving relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relat           | tionships/conditions/circumstances that present a potential conflict of interest   |
|                            | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rals may ask authors to disclose further information about reported relationships. |
| Section 6.                 | Disclosure Statement   |
| Based on the abo<br>below. | ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. DENIS has no           | thing to disclose.   |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

DENIS 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Camps 1



| Section 1. Identifying Inform   | nation   |  |  |  |  |  |
|---|--|--|--|--|--|--|
| Given Name (First Name)  Carlos   | 2. Surname (Last Name)<br>Camps                              | 3. Date<br>19-March-2020   |  |  |  |  |
| 4. Are you the corresponding author?  | ☐ Yes 🗸 No   | Corresponding Author's Name<br>Naixin Liang  |  |  |  |  |
| 5. Manuscript Title Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q |  |  |  |  |  |  |
| 6. Manuscript Identifying Number (if you k<br>JTD-20-1004(AZ-2019-CR-02-F)                              | now it)  |  |  |  |  |  |
|   |  |  |  |  |  |  |
| Section 2. The Work Under C   | onsideration for Public                                      | cation   |  |  |  |  |
|   | g but not limited to grants, da                              | a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,   |  |  |  |  |
|   |  |  |  |  |  |  |
| Section 3. Relevant financial   | activities outside the s                                     | submitted work.  |  |  |  |  |
| of compensation) with entities as descr   | ribed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |  |  |  |  |
|   |  |  |  |  |  |  |
| Section 4. Intellectual Prope   | rty Patents & Copyric  | ghts   |  |  |  |  |
| Do you have any patents, whether plan   | nned, pending or issued, br                                  | oadly relevant to the work? Yes V No   |  |  |  |  |

Camps 2



| Section 5.       |  |
|------------------|--|
| Section 5.       | Relationships not covered above  |
|                  | relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?   |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela  | ationships/conditions/circumstances that present a potential conflict of interest  |
|                  | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>Irnals may ask authors to disclose further information about reported relationships. |
|                  |  |
| Section 6.       | Disclosure Statement   |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Camps has n  | othing to disclose.  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Camps 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Fernandez-Diaz 1



| Section 1.                                   | Identifying Inform                                   | nation  |  |
|--|--|---|--|
| 1. Given Name (Fi<br>Amaya B.                | rst Name)  | 2. Surname (Last Name)<br>Fernandez-Diaz  | 3. Date<br>19-March-2020   |
| 4. Are you the cor                           | responding author?                                   | Yes ✓ No Corresponding Author's Name Naixin Liang   |  |
| 5. Manuscript Title<br>Potential treatme     |  | e osimertinib resistant mu  | tation EGFR L718Q  |
| 6. Manuscript Ider<br>JTD-20-1004(AZ-        | ntifying Number (if you kr<br>-2019-CR-02-F)         | now it)   |  |
|  |  |   |  |
| Section 2.                                   | The Work Under C                                     | onsideration for Public   | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                             | g but not limited to grants, da   | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation,   |
| Section 3.                                   | Relevant financial                                   | activities outside the s  | submitted work.  |
| of compensation clicking the "Add            | the appropriate boxes i<br>) with entities as descri | in the table to indicate who<br>ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication. |
| Section 4.                                   | Intellectual Proper                                  | rty Patents & Copyrig   | yhts   |
| Do you have any                              | patents, whether plan                                | ned, pending or issued, br  | oadly relevant to the work? Yes V No   |

Fernandez-Diaz 2



| Section 5.       |  |
|------------------|--|
| Section 5.       | Relationships not covered above  |
|                  | relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?   |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rela  | ationships/conditions/circumstances that present a potential conflict of interest  |
|                  | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>Irnals may ask authors to disclose further information about reported relationships. |
| Section 6.       | Disclosure Statement   |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box  |
| Dr. Fernandez-D  | Diaz has nothing to disclose.  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Fernandez-Diaz 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Liang 1



| Section 1. Identifying Inform   | ation                        |                     |            |  |
|---|------------------------------|---------------------|------------|--|
| 1. Given Name (First Name)<br>Nainxin   | 2. Surname (Last Na<br>Liang | me)                 |            | 3. Date<br>18-March-2020   |
| 4. Are you the corresponding author?  | ✓ Yes No                     |                     |            |  |
| 5. Manuscript Title<br>Potential treatment strategy for the rare  | osimertinib resista          | nt mutation EGFR    | L718Q      |  |
| 6. Manuscript Identifying Number (if you known JTD-20-1004(AZ-2019-CR-02-F)   | ow it)                       |                     |            |  |
| Continu 2   |                              |                     |            |  |
| Section 2. The Work Under Co  | nsideration for F            | Publication         |            |  |
| Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)? |                              |                     |            |  |
| Are there any relevant conflicts of intere  | st? 🗸 Yes                    | No                  |            |  |
| If yes, please fill out the appropriate info  |                              | ou have more than   | n one enti | ty press the "ADD" button to add a ro  |
| Excess rows can be removed by pressing  |                              | Non-Financial       |            |  |
| Name of Institution/Company   | Grant? Personal Fees?        | Support?            | Other?     | Comments   |
| ijing Natural Science Foundation  | <b>✓</b>                     |                     |            | No.7182132   |
| inistry of Science and Technology of the<br>cople's Republic of China   | <b>V</b>                     |                     |            | Special Data Service for Oncology,<br>The National Population and Health<br>Scientific Data Sharing Platform<br>(NCMI-ABD02-201809; NCMI-<br>YF02N-201906) |
| ninese Academy of Medical Sciences Young<br>edical Talent Award Fund  | <b>✓</b>                     |                     |            | No.2018RC320005  |
| jing Students' platform for innovation and<br>trepreneurship training program   | <b>V</b>                     |                     |            | No.2019zlgc0629  |
|   |                              |                     |            |  |
|   |                              |                     |            |  |
| Section 3. Relevant financial a   | activities outside           | the submitted       | work.      |  |
| Place a check in the appropriate boxes ir of compensation) with entities as describlicking the "Add +" box. You should rep    | oed in the instruction       | ons. Use one line f | or each er | ntity; add as many lines as you need by  |
| Are there any relevant conflicts of intere  | st? Yes ✓                    | No                  |            |  |

Liang 2



| Soutien A   |
|---|
| Section 4. Intellectual Property Patents & Copyrights   |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo   |
| Section 5. Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?   |
| Yes, the following relationships/conditions/circumstances are present (explain below):  |
| No other relationships/conditions/circumstances that present a potential conflict of interest   |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.   |
| Section 6. Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.   |
| Dr. Liang reports grants from Beijing Natural Science Foundation, grants from Ministry of Science and Technology of the People's Republic of China, grants from Chinese Academy of Medical Sciences Young Medical Talent Award Fund, grants from Bejing Students' platform for innovation and entrepreneurship training program, during the conduct of the study; . |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Liang 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Li 1



| Section 1.                                   | Identifying Inform                                   | nation   |  |   |
|--|--|--|--|---|
| 1. Given Name (Fi<br>Shanqing                | rst Name)  | 2. Surname (Last Name)<br>Li   |  | 3. Date<br>18-March-2020  |
| 4. Are you the cor                           | responding author?                                   | ✓ Yes No   |  |   |
| 5. Manuscript Title<br>Potential treatme     |  | e osimertinib resistant mu   | tation EGFR L718Q  |   |
| 6. Manuscript lder<br>JTD-20-1004(AZ-        | ntifying Number (if you kr<br>-2019-CR-02-F)         | now it)  | _  |   |
|  | ı  |  |  |   |
| Section 2.                                   | The Work Under Co                                    | onsideration for Publi   | cation   |   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                             | but not limited to grants, d   |  | ommercial, private foundation, etc.) for esign, manuscript preparation,                         |
| Section 3.                                   | Relevant financial                                   | activities outside the   | submitted work   |   |
| of compensation clicking the "Add            | the appropriate boxes i<br>) with entities as descri | in the table to indicate whibed in the instructions. Uport relationships that we | ether you have financial rel<br>se one line for each entity; a | lationships (regardless of amount add as many lines as you need by nonths prior to publication. |
| Section 4.                                   | Intellectual Proper                                  | rty Patents & Copyri   | ghts   |   |
| Do you have any                              | patents, whether plan                                | ned, pending or issued, b  | roadly relevant to the work?                                   | ? ☐ Yes ✓ No  |

Li 2



| Section 5.        |   |
|-------------------|---|
|                   | Relationships not covered above   |
|                   | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?   |
| Yes, the follow   | wing relationships/conditions/circumstances are present (explain below):  |
| ✓ No other rela   | tionships/conditions/circumstances that present a potential conflict of interest  |
|                   | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.        | Disclosure Statement  |
| Based on the abo  | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. Li has nothin | g to disclose.  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Li 3